Patent ID: 11904002
Assignee: BOSTONGENE CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  G  C | IPC A  C  G

Claim 0:
1. A method comprising:
a) obtaining information relating to a TMPRSS2/ERG gene fusion in a biological sample from a subject having or suspected of having cancer;
b) obtaining information relating to one or more HLA alleles of the subject having or suspected of having cancer;
c) selecting two or more two or more TMPRSS2/ERG fusion-derived neoantigen peptides from a library consisting of a plurality of containers, each respective container of the plurality containing a respective fusion-derived neoantigen peptide consisting of a respective sequence set forth in SEQ ID NOs: 1-403, wherein each selected TMPRSS2/ERG fusion-derived neoantigen peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 374-381;
d) determining binding of the selected TMPRSS2/ERG fusion-derived neoantigen peptides of (c) to the one or more HLA alleles of the subject;
e) selecting at least one of the TMPRSS2/ERG fusion-derived neoantigen peptides for administration to the subject when the TMPRSS2/ERG fusion-derived neoantigen peptide is determined to bind to the one or more HLA alleles of the subject; and
f) administering a peptide vaccine comprising the selected TMPRSS2/ERG fusion-derived neoantigen peptide of (e) to the subject; and
g) monitoring tumor growth or formation in the subject after administering the one or more fusion peptides of (f) to the subject.